| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
32,130,000 |
| Market
Cap: |
167.08(M) |
| Last
Volume: |
33,837 |
Avg
Vol: |
33,744 |
| 52
Week Range: |
$2.94 - $6.39 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 5.8 |
| Insider 6 Months : 7.8 |
| Insider 3/6 Months : 14 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Co.'s primary focus is on the development of its primary product candidate, DefenCath™, for potential commercialization in the U.S. and other main markets. Co. has in-licensed the worldwide rights to develop and commercialize DefenCath and Neutrolin®. DefenCath/Neutrolin is an anti-infective solution intended for the reduction of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis and total parenteral nutrition.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
13,561 |
20,561 |
64,561 |
104,261 |
| Total Buy Value |
$50,718 |
$74,968 |
$265,441 |
$412,965 |
| Total People Bought |
1 |
3 |
6 |
6 |
| Total Buy Transactions |
1 |
4 |
10 |
14 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Todisco Joseph |
Chief Executive Officer |
• • – |
2023-05-10 |
4 |
D |
$5.30 |
$198,448 |
D/D |
(37,443) |
204,726 |
|
- |
|
| Stewart Robert A |
|
– • – |
2023-04-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,000 |
|
-21% |
|
| Mistry Erin |
Chief Commercial OfficerOffice |
• – – |
2023-01-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,900 |
|
8% |
|
| Todisco Joseph |
Chief Executive Officer |
• • – |
2022-11-15 |
4 |
B |
$3.82 |
$76,400 |
D/D |
20,000 |
242,169 |
2.81 |
-1% |
|
| Todisco Joseph |
Chief Executive Officer |
• • – |
2022-08-24 |
4 |
B |
$3.92 |
$18,424 |
D/D |
4,700 |
222,169 |
0.01 |
13% |
|
| Kaplan Myron |
Director |
– • – |
2022-05-17 |
4 |
B |
$3.78 |
$18,900 |
D/D |
5,000 |
160,034 |
2.39 |
-24% |
|
| Todisco Joseph |
Chief Executive Officer |
• • – |
2022-05-16 |
4 |
B |
$3.38 |
$33,800 |
D/D |
10,000 |
217,469 |
0.01 |
-19% |
|
| Todisco Joseph |
Chief Executive Officer |
• • – |
2022-05-10 |
4 |
A |
$0.00 |
$0 |
D/D |
207,469 |
207,469 |
|
- |
|
| Kaplan Myron |
|
– • – |
2021-12-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
35,000 |
140,034 |
|
- |
|
| David Matthew T |
Interim CEO and CFO |
• – – |
2021-12-06 |
4 |
B |
$4.50 |
$4,500 |
D/D |
1,000 |
3,150 |
0.01 |
2% |
|
| David Matthew T |
Interim CEO and CFO |
• – – |
2021-11-17 |
4 |
B |
$5.07 |
$5,070 |
D/D |
1,000 |
2,150 |
0.01 |
8% |
|
| Kaplan Myron |
|
– • – |
2021-11-16 |
4 |
B |
$5.14 |
$51,400 |
D/D |
10,000 |
175,034 |
0.01 |
13% |
|
| Masson Elizabeth |
EVP, Head of Clinical Ops |
• – – |
2021-05-21 |
4 |
S |
$6.92 |
$55,394 |
D/D |
(8,000) |
0 |
|
32% |
|
| Kaplan Myron |
Director |
– • – |
2021-05-17 |
4 |
B |
$6.03 |
$90,477 |
D/D |
15,000 |
165,034 |
2.39 |
-25% |
|
| Lefkowitz Steven W |
|
– • – |
2020-09-04 |
4 |
B |
$3.98 |
$22,816 |
D/D |
5,715 |
60,498 |
0.01 |
125% |
|
| David Matthew T |
Chief Financial Officer |
• – – |
2020-09-03 |
4 |
B |
$4.07 |
$4,681 |
D/D |
1,150 |
1,150 |
0.01 |
118% |
|
| Kaplan Myron |
|
– • – |
2020-09-02 |
4 |
B |
$4.27 |
$65,359 |
D/D |
15,300 |
150,034 |
0.01 |
108% |
|
| Khan Mehmood |
|
– • – |
2020-08-19 |
4 |
B |
$4.90 |
$87,472 |
D/D |
17,837 |
178,767 |
0.01 |
51% |
|
| Khan Mehmood |
|
– • – |
2020-08-18 |
4 |
B |
$4.60 |
$133,878 |
D/D |
27,913 |
160,930 |
0.01 |
53% |
|
| Armstrong John L Jr |
Exec VP of Tech Operations |
• – – |
2020-08-14 |
4 |
B |
$4.14 |
$116,110 |
D/D |
27,500 |
96,878 |
0.01 |
71% |
|
| Mounts Phoebe |
General Counsel |
• – – |
2020-08-13 |
4 |
B |
$4.03 |
$10,176 |
D/D |
2,525 |
7,200 |
0.01 |
89% |
|
| Kaplan Myron |
|
– • – |
2020-08-13 |
4 |
B |
$4.08 |
$61,160 |
D/D |
15,000 |
134,734 |
0.01 |
89% |
|
| Baluch Khoso |
Chief Executive Officer |
• • – |
2020-08-13 |
4 |
B |
$4.14 |
$19,985 |
D/D |
4,830 |
60,905 |
0.01 |
89% |
|
| Dunton Alan W |
|
– • – |
2020-08-12 |
4 |
B |
$3.95 |
$19,750 |
D/D |
5,000 |
6,250 |
0.01 |
114% |
|
| Kaplan Myron |
|
– • – |
2020-05-15 |
4 |
B |
$3.85 |
$38,500 |
D/D |
10,000 |
119,734 |
0.01 |
31% |
|
260 Records found
|
|
Page 2 of 11 |
|
|
0.05 (0.95%) 
